Literature DB >> 9727773

High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.

M Delcroix1, X Kurz, D Walckiers, M Demedts, R Naeije.   

Abstract

Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs. The importance of this association was evaluated in Belgium while this country still had no restriction on the prescription of appetite suppressants. Thirty-five patients with primary pulmonary hypertension and 85 matched controls were recruited over 32 months (1992-1994) in Belgium. Exposure to appetite-suppressants was assessed on the basis of hospital records and standardized interview. Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001). Five patients died before the interview, all of them had taken appetite suppressants. In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken appetite suppressants. The patients who had been exposed to appetite suppressants tended to be on average more severely ill, and to have a shorter median delay between onset of symptoms and diagnosis. A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension. Intake of appetite suppressants may accelerate the progression of the disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9727773     DOI: 10.1183/09031936.98.12020271

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

Review 1.  Primary pulmonary hypertension.

Authors:  A J Peacock
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

2.  Insulin resistance in pulmonary arterial hypertension.

Authors:  R T Zamanian; G Hansmann; S Snook; D Lilienfeld; K M Rappaport; G M Reaven; M Rabinovitch; R L Doyle
Journal:  Eur Respir J       Date:  2008-12-01       Impact factor: 16.671

Review 3.  Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.

Authors:  Marcelo O Dietrich; Tamas L Horvath
Journal:  Nat Rev Drug Discov       Date:  2012-08-03       Impact factor: 84.694

Review 4.  Safety of drug therapies used for weight loss and treatment of obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; Andrew M Tonkin; John J McNeil
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome.

Authors:  W Budts; N Van Pelt; H Gillyns; M Gewillig; F Van De Werf; S Janssens
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

Review 6.  The protease-antiprotease battle in the cystic fibrosis lung.

Authors:  I M Balfour-Lynn
Journal:  J R Soc Med       Date:  1999       Impact factor: 18.000

7.  Pharmacotherapies for obesity: past, current, and future therapies.

Authors:  Lisa L Ioannides-Demos; Loretta Piccenna; John J McNeil
Journal:  J Obes       Date:  2010-12-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.